2007年瑞士Cytos公司搞了个与阿利沙坦同靶点的疫苗药CYT006-AngQb,当时在动物上没问题,在人体IIa期时就挂了。该疫苗免疫后生成针对血管紧张素Ⅱ(AngⅡ)抗体,该抗体通过中和AngⅡ发挥降压作用,但由于存在RAS反馈激活现象,AngⅡ被中和后不可避免的导致肾素激活,最终生成更多的AngⅡ,削弱了该疫苗的降压效果。 当前报...
CYT006-AngQb is a therapeutic vaccine in development for treatment of hypertension. It is designed to instruct the patient’s immune system to produce an antibody response against angiotensin II, a small peptide that causes blood vessels to narrow and results in increased blood pressure. It is ...
AHA 2007年会上公布了瑞士cytos生物技术公司关于血管紧张素Ⅱ(Ang Ⅱ)与病毒样颗粒融和疫苗(CYT006-AngQb)的Ⅱa期临床研究结果,证明该疫苗在人体应用安全有效。 该项多中心、随机、双盲、安慰剂对照研究以72例轻至中度高血压患者为对象,将其分入CYT006-AngQb 100 μg组、300 μg组或安慰剂组,分别于0、4、...
CYT-006-AngQb, under development by Cytos Biotechnology AG, is a vaccine in which a peptide derived from the angiotensin II molecule is conjugated to the surface of the highly repetitive structure of virus-like particles. CYT-006-AngQb was designed to treat hypertension with the benefit of re...
CYT006-AngQb, a virus-like-particle based conjugate vaccine targeting angiotensin II (Ang II), was shown to induce antibodies against Ang II and to reduce day-time ambulatory systolic blood pressure (SBP) in a multicenter, double blind, randomized, placebo-controlled phase IIa...
CYT 006 AngQb,a vaccine designed to produce a specific anti-angiotensin II antibody response, has beneficial effects in patients with mild to moderate hypertension
Researchers believe immunisation with CYT006-AngQb was associated with no serious adverse events and the 300碌g dose reduced blood pressure in patients with mild-to-moderate hypertension while the 110碌g did not.EBSCO_bspLancet
CYT 006 AngQb vaccine shows promise for hypertensionInpharma Weekly -doi:10.2165/00128413-200715730-00012NoneSpringer International PublishingInpharma Weekly
Biotechnology Reports Biochemical Findings From Phase IIa Study With Hypertension Vaccine CYT006-AngQb
作者调查研究了疫苗CYT006-AngQb用于高血压患者的安全性及有效性,该疫苗的制备基于病毒样颗粒,其靶点是血管紧张素Ⅱ,以期降低动态血压。方法在此项多中心、双盲、随机、安慰剂对照的Ⅱa期试验中,以计算机随机抽样的方式将72例轻至中度高血压患者随机分组,分别于第0、4、12周时皮下注射接种CYT006-AngQb疫苗100μg...